OncoCyte Overview
Latest P/E ratio for OncoCyte: -2.72 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-2.72
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for 0KCC.L is -2.72. That is below the sector sector average of 33.83. Investors often review this figure alongside OncoCyte's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 0KCC.L currently prints -2.72 for P/E ratio, while the sector average sits near 33.83. That is roughly 108.0% below the sector mean. Large gaps often invite a closer look at OncoCyte's growth, margins, and balance sheet.
A P/E ratio of -2.72 for OncoCyte is not 'good' or 'bad' on its own. Compare it with the peer average (33.83) and with 0KCC.L's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting 0KCC.L's P/E ratio (-2.72), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
